U.S. drugmakers are charging significantly more for new treatments, particularly those targeting rare diseases, as the median ...

Uijeongbu Eulji University Hospital said Professor Kim Dong-wook's team of hematology department proved that KF1601, a ...

The "One Big Beautiful Bill Act" includes negotiation exemptions for orphan drugs approved to treat more than one rare ...

Drugs being explicitly developed to treat rare diseases are getting more expensive. An analysis by Reuters found that prices ...

Prices of newly launched drugs in the U.S. have more than doubled from 2021 to 2024, driven by rare disease therapies, ...

U.S. prices for new drugs more than doubled last year compared to 2021, as companies developed more therapies for rare ...

U.S. President Donald Trump's trade negotiators are pushing the EU to make unilateral tariff reductions on U.S. goods, saying ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

ASX biotechs have become well-known for paediatric drug discovery with several life-altering treatments exported to the world.

Eton Pharmaceuticals is able to buy orphan drugs from large pharma companies, where they are too small to matter. Read why ...

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, ...